medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Number 6

<< Back Next >>

Rev Mex Urol 2025; 85 (6)

Immune response determines the outcome in renal cell carcinoma

González GR, Gutiérrez GA, Salinas CMC, López LN, Garza GR, Mejía TM

Language: English
References: 45
Page: 1-13
PDF size: 698.73 Kb.


ABSTRACT

Renal cell carcinoma (RCC) is a significant health burden that is associated with morbidity and mortality. Factors exacerbating the challenges of this condition include late diagnosis, intrinsic resistance to chemotherapy, and the cellular heterogeneity of tumors. In addition, the role of immunity in this condition was suggested by the successful use of immunotherapy in advanced RCC, which requires an understanding of the underlying immunopathological mechanisms involved in the progression of the disease. Moreover, the functional status of infiltrated immune cells and histological tumor subtypes could be used as predictive tools for selecting individualized treatments. This review summarizes the available information on the role of immunity in clinical outcomes and response to treatment in patients diagnosed with RCC.


REFERENCES

  1. Bray F, Laversanne M, Sung H, Ferlay J,Siegel RL, Soerjomataram I, et al. Globalcancer statistics 2022: GLOBOCAN estimatesof incidence and mortality worldwide for 36cancers in 185 countries. CA: a cancer journalfor clinicians. 2024;74(3): 229–263. https://doi.org/10.3322/caac.21834.

  2. Azawi NH, Tesfalem H, Mosholt KSS, HøyerupP, Jensen ES, Malchau E, et al. Recurrence ratesand survival in a Danish cohort with renal cellcarcinoma. Danish Medical Journal. 2016;63(4):A5208.

  3. Mohanty SK, Lobo A, Cheng L. The 2022revision of the World Health Organizationclassification of tumors of the urinary system andmale genital organs: advances and challenges.Human Pathology. 2023;136: 123–143. https://doi.org/10.1016/j.humpath.2022.08.006.

  4. World Health Organization. WHOClassification of Tumours Online. 2025. https://tumourclassification.iarc.who.int/welcome/

  5. Muglia VF, Prando A. Renal cell carcinoma:histological classification and correlationwith imaging findings. Radiologia Brasileira.2015;48(3): 166–174. https://doi.org/10.1590/0100-3984.2013.1927.

  6. Karthika C, Sureshkumar R, Zehravi M,Akter R, Ali F, Ramproshad S, et al. MultidrugResistance of Cancer Cells and the Vital Roleof P-Glycoprotein. Life (Basel, Switzerland).2022;12(6): 897. https://doi.org/10.3390/life12060897.

  7. Koury J, Lucero M, Cato C, Chang L, Geiger J,Henry D, et al. Immunotherapies: Exploiting theImmune System for Cancer Treatment. Journalof Immunology Research. 2018;2018: 9585614.https://doi.org/10.1155/2018/9585614.

  8. Mukherjee AG, Wanjari UR, NamachivayamA, Murali R, Prabakaran DS, Ganesan R, et al.Role of Immune Cells and Receptors in CancerTreatment: An Immunotherapeutic Approach.Vaccines. 2022;10(9): 1493. https://doi.org/10.3390/vaccines10091493.

  9. Chen W, Pan X, Cui X. RCC ImmuneMicroenvironment Subsequent to TargetedTherapy: A Friend or a Foe? Frontiers in Oncology.2020;10: 573690. https://doi.org/10.3389/fonc.2020.573690.

  10. Fujita K, Kimura G, Tsuzuki T, Kato T, BannoE, Kazama A, et al. The Association of TumorImmune Microenvironment of the PrimaryLesion with Time to Metastasis in Patientswith Renal Cell Carcinoma: A RetrospectiveAnalysis. Cancers. 2022;14(21): 5258. https://doi.org/10.3390/cancers14215258.

  11. Sarkar M, Nguyen T, Gundre E, Ogunlusi O,El-Sobky M, Giri B, et al. Cancer-associatedfibroblasts: The chief architect in the tumormicroenvironment. Frontiers in Cell andDevelopmental Biology. 2023;11: 1089068.https://doi.org/10.3389/fcell.2023.1089068.

  12. Mirlekar B. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications incancer immunotherapy. SAGE open medicine.2022;10: 20503121211069012. https://doi.org/10.1177/20503121211069012.

  13. Zhang Y, Zhang S, Sun H, Xu L. The pathogenesisand therapeutic implications of metabolicreprogramming in renal cell carcinoma. CellDeath Discovery. 2025;11(1): 186. https://doi.org/10.1038/s41420-025-02479-9.

  14. SALINAS-CARMONA MC, DE LA GARZA J.TNMI may improve current cancer staging.Jornal of Cancerology. 2019;6: 28–30.

  15. Rosales-Velázquez CE, Gallegos-Sánchez G,Montaño-Roca BE, Ruvalcaba-Oceguera GE,Rosales-Velázquez CE, Gallegos-Sánchez G,et al. Abordaje laparoscópico vs abierto para eltratamiento quirúrgico de los tumores renales:Experiencia en el Centro Médico ISSEMyMToluca, México. Revista mexicana de urología.2020;80(1). https://doi.org/10.48193/rmu.v80i1.586.

  16. Roos FC, Steffens S, Junker K, Janssen M,Becker F, Wegener G, et al. Survival advantageof partial over radical nephrectomy in patientspresenting with localized renal cell carcinoma.BMC Cancer. 2014;14: 372. https://doi.org/10.1186/1471-2407-14-372.

  17. Lalani AKA, Heng DYC, Basappa NS,Wood L, Iqbal N, McLeod D, et al. Evolvinglandscape of first-line combination therapyin advanced renal cancer: a systematic review.Therapeutic Advances in Medical Oncology.2022;14: 17588359221108685. https://doi.org/10.1177/17588359221108685.

  18. Pevzner AM, Tsyganov MM, Ibragimova MK,Litvyakov NV. Abscopal effect in the radio andimmunotherapy. Radiation Oncology Journal.2021;39(4): 247–253. https://doi.org/10.3857/roj.2021.00115.

  19. Thomson RJ, Moshirfar M, Ronquillo Y.Tyrosine Kinase Inhibitors. In: StatPearls.Treasure Island (FL): StatPearls Publishing;

  20. 2025. http://www.ncbi.nlm.nih.gov/books/NBK563322/ [Accessed 12th December 2025].20. Vento JA, Rini BI. Treatment of RefractoryMetastatic Renal Cell Carcinoma. Cancers.2022;14(20): 5005. https://doi.org/10.3390/cancers14205005.

  21. Chang E, Weinstock C, Zhang L, Fiero MH,Zhao M, Zahalka E, et al. FDA ApprovalSummary: Tivozanib for Relapsed or RefractoryRenal Cell Carcinoma. Clinical Cancer Research:An Official Journal of the American Associationfor Cancer Research. 2022;28(3): 441–445.https://doi.org/10.1158/1078-0432.CCR-21-2334.

  22. Jaafar J, Fernandez E, Alwan H, Philippe J.Programmed cell death-1 and programmedcell death ligand-1 antibodies-induceddysthyroidism. Endocrine Connections.2018;7(5): R196–R211. https://doi.org/10.1530/EC-18-0079.

  23. Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y,et al. Improvement of the anticancer efficacy ofPD-1/PD-L1 blockade via combination therapyand PD-L1 regulation. Journal of Hematology& Oncology. 2022;15(1): 24. https://doi.org/10.1186/s13045-022-01242-2.

  24. Motzer RJ, Escudier B, McDermott DF, GeorgeS, Hammers HJ, Srinivas S, et al. Nivolumabversus Everolimus in Advanced Renal-CellCarcinoma. New England Journal of Medicine.2015;373(19): 1803–1813. https://doi.org/10.1056/NEJMoa1510665.

  25. Tannir NM, Albigès L, McDermott DF,Burotto M, Choueiri TK, Hammers HJ, et al.Nivolumab plus ipilimumab versus sunitinibfor first-line treatment of advanced renal cellcarcinoma: extended 8-year follow-up resultsof efficacy and safety from the phase IIICheckMate 214 trial. Annals of Oncology: OfficialJournal of the European Society for MedicalOncology. 2024;35(11): 1026–1038. https://doi.org/10.1016/j.annonc.2024.07.727.

  26. Takamatsu K, Tanaka N, Hakozaki K,Takahashi R, Teranishi Y, Murakami T, etal. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinomareveals malignancy. Nature Communications.2021;12(1): 5547. https://doi.org/10.1038/s41467-021-25865-0.

  27. Rini BI, Plimack ER, Stus V, Gafanov R,Hawkins R, Nosov D, et al. Pembrolizumabplus Axitinib versus Sunitinib for AdvancedRenal-Cell Carcinoma. New England Journal ofMedicine. 2019;380(12): 1116–1127. https://doi.org/10.1056/NEJMoa1816714.

  28. Motzer RJ, Penkov K, Haanen J, Rini B,Albiges L, Campbell MT, et al. Avelumabplus Axitinib versus Sunitinib for AdvancedRenal-Cell Carcinoma. New England Journal ofMedicine. 2019;380(12): 1103–1115. https://doi.org/10.1056/NEJMoa1816047.

  29. Rini BI, Powles T, Atkins MB, Escudier B,McDermott DF, Suarez C, et al. Atezolizumabplus bevacizumab versus sunitinib in patientswith previously untreated metastatic renal cellcarcinoma (IMmotion151): a multicentre, openlabel,phase 3, randomised controlled trial. TheLancet. 2019;393(10189): 2404–2415. https://doi.org/10.1016/S0140-6736(19)30723-8.

  30. Choueiri TK, Powles T, Burotto M, Escudier B,Bourlon MT, Zurawski B, et al. Nivolumab plusCabozantinib versus Sunitinib for AdvancedRenal-Cell Carcinoma. New England Journal ofMedicine. 2021;384(9): 829–841. https://doi.org/10.1056/NEJMoa2026982.

  31. Motzer R, Alekseev B, Rha SY, Porta C,Eto M, Powles T, et al. Lenvatinib plusPembrolizumab or Everolimus for AdvancedRenal Cell Carcinoma. New England Journal ofMedicine. 2021;384(14): 1289–1300. https://doi.org/10.1056/NEJMoa2035716.

  32. Powles T, Plimack ER, Soulières D, WaddellT, Stus V, Gafanov R, et al. Pembrolizumabplus axitinib versus sunitinib monotherapyas first-line treatment of advanced renal cellcarcinoma (KEYNOTE-426): extended followupfrom a randomised, open-label, phase 3trial. The Lancet. Oncology. 2020;21(12):1563–1573. https://doi.org/10.1016/S1470-2045(20)30436-8.

  33. Pal SK, Albiges L, Tomczak P, Suárez C,Voss MH, de Velasco G, et al. Atezolizumabplus cabozantinib versus cabozantinibmonotherapy for patients with renal cellcarcinoma after progression with previousimmune checkpoint inhibitor treatment(CONTACT-03): a multicentre, randomised,open-label, phase 3 trial. Lancet (London,England). 2023;402(10397): 185–195. https://doi.org/10.1016/S0140-6736(23)00922-4.

  34. Tannir NM, Formiga MN, Penkov K, KislovN, Vasiliev A, Gunnar Skare N, et al.Bempegaldesleukin Plus Nivolumab VersusSunitinib or Cabozantinib in PreviouslyUntreated Advanced Clear Cell Renal CellCarcinoma: A Phase III Randomized Study(PIVOT-09). Journal of Clinical Oncology:Official Journal of the American Society of ClinicalOncology. 2024;42(23): 2800–2811. https://doi.org/10.1200/JCO.23.02082.

  35. Buechner J, Kersten MJ, Fuchs M, SalmonF, Jäger U. Chimeric Antigen Receptor-TCell Therapy: Practical Considerations forImplementation in Europe. HemaSphere.2018;2(1): e18. https://doi.org/10.1097/HS9.0000000000000018.

  36. Maude SL, Barrett D, Teachey DT, GruppSA. Managing cytokine release syndromeassociated with novel T cell-engagingtherapies. Cancer Journal (Sudbury, Mass.).2014;20(2): 119–122. https://doi.org/10.1097/PPO.0000000000000035.

  37. Campos NSP de, Souza BS, Silva GCP da, PortoVA, Chalbatani GM, Lagreca G, et al. CarbonicAnhydrase IX: A Renewed Target for CancerImmunotherapy. Cancers. 2022;14(6): 1392.https://doi.org/10.3390/cancers14061392.

  38. Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F,et al. Tumor buster - where will the CAR-Tcell therapy ‘missile’ go? Molecular Cancer.2022;21(1): 201. https://doi.org/10.1186/s12943-022-01669-8.

  39. Li X, Zhang Y, Ye Y, Xiao W, Liu L, ZhangX. NK cells in renal cell carcinoma and itsimplications for CAR-NK therapy. Frontiers inCell and Developmental Biology. 2025;13. https://doi.org/10.3389/fcell.2025.1532491.

  40. Wang QT, Nie Y, Sun SN, Lin T, Han RJ,Jiang J, et al. Tumor-associated antigenbasedpersonalized dendritic cell vaccinein solid tumor patients. Cancer immunology,immunotherapy: CII. 2020;69(7): 1375–1387.https://doi.org/10.1007/s00262-020-02496-w.

  41. Miricescu D, Balan DG, Tulin A, Stiru O,Vacaroiu IA, Mihai DA, et al. PI3K/AKT/mTORsignalling pathway involvement in renal cellcarcinoma pathogenesis (Review). Experimentaland Therapeutic Medicine. 2021;21(5): 540.https://doi.org/10.3892/etm.2021.9972.

  42. Ye X, Ruan JW, Huang H, Huang WP, Zhang Y,Zhang F. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growthin vitro and in vivo. Aging. 2020;12(10): 9489–9499. https://doi.org/10.18632/aging.103221.

  43. Shah AY, Kotecha RR, Lemke EA,Chandramohan A, Chaim JL, Msaouel P, et al.Outcomes of patients with metastatic clear-cellrenal cell carcinoma treated with second-lineVEGFR-TKI after first-line immune checkpointinhibitors. European Journal of Cancer (Oxford,England: 1990). 2019;114: 67–75. https://doi.org/10.1016/j.ejca.2019.04.003.

  44. Choueiri TK, Bauer TM, Papadopoulos KP,Plimack ER, Merchan JR, McDermott DF, etal. Inhibition of hypoxia-inducible factor-2α inrenal cell carcinoma with belzutifan: a phase 1trial and biomarker analysis. Nature Medicine. 2021;27(5): 802–805. https://doi.org/10.1038/s41591-021-01324-7.

  45. Lorentzen CL, Haanen JB, Met Ö, Svane IM.Clinical advances and ongoing trials on mRNAvaccines for cancer treatment. The Lancet.Oncology. 2022;23(10): e450–e458. https://doi.org/10.1016/S1470-2045(22)00372-2.




2020     |     www.medigraphic.com